Catalog #SIM0091
InVivoSIM anti-human CD20 (Ublituximab Biosimilar)
Clone
Ublituximab
Reactivities
Human
Isotype
Human IgG1, κ
Product Description
This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ublituximab, making it ideal for research use. Ublituximab is a chimeric IgG1 monoclonal antibody that targets CD20, a transmembrane phosphoprotein expressed on pre‑B and mature B lymphocytes but not on plasma cells. CD20 is involved in B cell activation, proliferation, and calcium signaling. Ublituximab binds a unique epitope on CD20 and mediates potent B cell depletion primarily through antibody-dependent cellular cytotoxicity (ADCC). The original therapeutic antibody is glycoengineered for enhanced FcγRIIIa binding and effector function, though this research-grade biosimilar is not afucosylated. This Ublituximab biosimilar is ideal for exploring CD20 biology, B cell–mediated diseases, and mechanisms of B cell depletion in cancer and autoimmunity.
Specifications
| Isotype | Human IgG1, κ |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Mutations | E356D/M358L |
| Immunogen | Human CD20 |
| Reported Applications |
In vivo functional assays in vitro functional assays Flow cytometry ELISA |
| Formulation |
pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |